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Adherence to Antihypertensive Drugs 
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BACKGROUND: It is currently unknown if antihypertensive drugs can be monitored in oral fluid (OF) using liquid chromatography 
coupled to high-resolution mass spectrometry.
METHODS AND RESULTS: We assessed adherence using liquid chromatography coupled to high-resolution mass spectrom-
etry in OF, plasma, and urine of 56 consecutive patients with hypertension referred to a tertiary hypertension unit. Of these 
patients, 59% were completely adherent (all drugs detectable in urine), whereas 29% and 13% were partially adherent (1 
drug not detectable in urine) or nonadherent (>1 drug not detectable in urine), respectively. Adherent patients were on fewer 
antihypertensive drugs (P=0.001), had fewer daily drug doses (P=0.012), and had lower 24- hour ambulatory systolic (P=0.012) 
and diastolic (P=0.009) blood pressures than nonadherent or partially adherent patients. Most drugs were detected in urine 
compared with plasma and OF (181 versus 119 versus 88; P=0.001). Compared with urine and plasma, detection rates of 
angiotensin- converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics were lower in OF. There was no dif-
ference in the frequency of detecting β blockers (P=1.0) and calcium channel blockers (P=0.063) when comparing OF with 
urine. There was no difference in the number of calcium channel blockers (P=0.727), β blockers (P=1.000), thiazide diuretics 
(P=0.125), and α- 2 agonists (P=0.125) identified between OF and plasma.
CONCLUSIONS: This study shows the feasibility of drug adherence testing for several antihypertensive drugs, especially those 
without acidic components, in OF, with a similar recovery compared with plasma. Therefore, drug adherence testing in OF 
should be further explored as a noninvasive approach, which can easily be performed in an “out- of- office” setting.
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Nonadherence to prescribed drug treatment fre-quently occurs in hypertension and is associ-ated with increased morbidity and mortality.1–5 
Assessing drug adherence in hypertensive patients 
can guide specific patient- centered interventions to 
improve adherence and might reduce the number of 
unnecessarily prescribed drugs.6–8 Several indirect 
(pill count, patient diaries, adherence questionnaires, 
and prescription record reviews) and direct (drug 
monitoring in blood and urine and directly observed 
therapy) methods to evaluate adherence have been in-
troduced.9 Toxicological analyses of urine and plasma 
are the most commonly used matrices for assess-
ing drug adherence. However, the collection of both 
matrices bears potential disadvantages: collecting 
urine cannot be observed without infringing the pa-
tient’s privacy, whereas obtaining a blood sample is 
invasive and requires medical personnel. Furthermore, 
drug adherence monitoring in urine may cause false- 
positive results because the washout period for several 
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antihypertensive drugs in urine lasts longer than multi-
ple half- lives, usually exceeding 24 hours.10 Therefore, 
there is an unmet need for an easily applicable and reli-
able method to evaluate drug adherence.7,9,11 As drugs 
are in principle distributed to all body compartments, 
including oral fluids (OFs), the detection of drugs in OF 
may represent a novel approach in drug adherence 
testing. This study aimed at investigating liquid chro-
matography coupled to high-resolution mass spectrometry 
(LC- HRMS/MS) of urine, plasma, and OF to assess 
drug adherence in patients referred to an outpatient 
hypertension unit.
METHODS
The data of this investigator- initiated study are available 
from the corresponding author on reasonable request. 
Between November 2017 and March 2018, 56 con-
secutive patients with hypertension who were referred 
to the outpatient hypertension unit at the Saarland 
University Medical Center (Homburg/Saar, Germany) 
were included in this study. All participating patients 
provided written informed consent, and local ethics 
committees approved the study. Eligible patients were 
≥18 years old, had hypertension, as defined by current 
guidelines,12 and were prescribed to stable antihyper-
tensive therapy for at least 2 weeks.
Clinical Assessment
All patients were instructed to take their medication 
in the morning as prescribed. Medical history, physi-
cal examination, routine blood chemistry, and at-
tended office blood pressures were documented for 
all patients. After 5 minutes of rest in a comfortable, 
seated position, 3 consecutive blood pressure meas-
urements, 1 minute apart, were taken with a validated 
automated blood pressure monitor (Omron Health 
Care, Inc, Lake Forest, IL). If the first 2 readings var-
ied by >10 mm Hg, an additional measurement was 
performed. The last 2 blood pressure readings were 
averaged and recorded as the office blood pressure. 
Also, 24- hour ambulatory blood pressure monitoring 
(Mobil- O- Graph; I.E.M GmbH, Stolberg, Germany) 
was done where clinically indicated. Chronic kidney 
disease was defined as an estimated glomerular fil-
tration rate <60 mL/min per 1.73 m2. Chronic heart 
failure comprised patients with a history of chronic 
heart failure with and without reduced left ventricular 
ejection fraction.
Sampling of OF, Plasma, and Urine
OF was sampled in the morning using the Quantisal OF 
collection device (Immunalysis Corporation, Pomona, 
CA). The collection device consists of a collection pad 
that collects 1 mL (±10%) of OF and a transport tube 
containing liquid buffer. The device pad was placed 
under the patient’s tongue until the volume adequacy 
indicator turned blue. Of note, no chemical stimuli, such 
as acidic stimulation (citric acid), were used to increase 
salivation, as this might influence drug concentra-
tions.13 After sampling, the collection pad was inserted 
in the transport tube and was shaken for 2 hours at 
room temperature to allow the extraction of the OF 
from the collection pad. Afterward, the collection pad 
was removed. Venous EDTA blood and spot urinary 
samples were drawn, blood was centrifuged, and the 
supernatant was separated. Then, OF, plasma, and 
urine samples were stored at −20°C until the analysis 
was performed at the Department of Experimental and 
Clinical Toxicology at Saarland University (Homburg/
Saar, Germany).
Drug Adherence Analysis by LC- HRMS/
MS
The detailed bioanalytical method of the targeted 
adherence monitoring method has been described 
previously.14 In brief, samples were separated on 
a ThermoFisher Accucore PhyenylHexyl column 
CLINICAL PERSPECTIVE
What Is New?
• This is the first study that showed the feasibil-
ity of detecting several antihypertensive drugs, 
especially those without acidic components, in 
oral fluid (OF).
• Using liquid chromatography coupled to high-res-
olution mass spectrometry analysis, most antihy-
pertensive medications were identified in urine, 
followed by plasma and OF.
• Antihypertensive drugs without acidic compo-
nents had similar detection rates in plasma and 
OF, whereas antihypertensive drugs with acidic 
functions were poorly detected in OF.
What Are the Clinical Implications?
• Although most antihypertensive drugs were de-
tected in urine, drug adherence testing in OF, 
especially of substances without acidic compo-
nents, is feasible and should be further explored 
as a noninvasive approach, which can easily be 
performed in an “out-of-office” setting.
Nonstandard Abbreviations and Acronyms
LC-HRMS/MS  liquid chromatography coupled to 
high-resolution mass spectrometry
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(ThermoFisher, Dreieich, Germany) with mobile 
phase A consisting of 2 mmol/L aqueous ammonium 
formate containing 0.1% formic acid (v/v, pH 3) and 
mobile phase B consisting of 2 mmol/L aqueous am-
monium formate with acetonitrile:methanol (50:50, 
v/v, 1% water) containing 0.1% formic acid. Drugs 
and metabolites were analyzed by a ThermoFisher 
Scientific Dionex UltiMate 3000 (ThermoFisher) inter-
faced to an HTC PAL autosampler (CTC Analytics, 
Zwingen, Switzerland) and a TF Q- Exactive system 
with a heated electrospray ionization- II source set to 
positive/negative switching. Mass spectrometry was 
performed using full- scan data and a subsequent 
data- dependent acquisition mode with an inclusion 
list containing masses of interest. TraceFinder 4.1 
software (ThermoFisher) was used for data process-
ing. People assessing drug adherence were blinded 
to patients’ characteristics.
Definition of Adherence
Despite recent efforts to establish a standardized 
classification of medication adherence,15 the defini-
tions used in the literature remain inconsistent.16 We 
applied 2 commonly used classifications: In the first 
set of analyses, nonadherence was defined accord-
ing to the absolute number of nondetectable drugs. 
If all prescribed drugs were detectable in urine, a pa-
tient was classified as “adherent.” If 1 or at least 2 of 
the prescribed drugs were not detectable, the patient 
was considered to be “partially adherent” and “non-
adherent,” respectively. In the second set of analyses, 
provided in Tables S1 and S2, adherence was defined 
dichotomously on the basis of a threshold of 80%. If 
≥80% of the prescribed drugs were detectable in urine, 
the patient was classified as “adherent.” Otherwise, 
the patient was considered to be “nonadherent.” For 
analyses of clinical characteristics, adherence to all 
substances of a single- pill combination was assumed, 
if at least one component of a single- pill combination 
was detectable (referred to as “adherence corrected 
for single- pill combinations”).
Statistical Analysis
Data are presented as mean±SD and numbers (per-
centages). Because of the relatively low sample size, 
we used the Wilcoxon matched- pairs signed- rank 
test and the Mann- Whitney test to compare continu-
ous variables between 2 paired and unpaired groups, 
respectively. The Kruskal- Wallis test was used for 
comparisons of continuous data between adherent, 
partially adherent, and nonadherent patients. If the 
Kruskal- Wallis test was significant, we used the Dunn- 
Bonferroni post hoc method for pairwise comparisons. 
For categorical variables, comparisons between inde-
pendent groups were performed using Pearson’s χ2 or 
Fisher’s exact test, whereas McNemar’s or Cochran’s 
Q test was used for paired groups. For nominal vari-
ables, we used Fleiss’ K to assess reliability. Interrater 
reliability was interpreted as initially suggested, with a 
K <0 tentatively considered to be poor; 0 to 0.2, slight; 
0.21 to 0.40, fair; 0.41 to 0.60, moderate; 0.61 to 0.80, 
substantial; and 0.81 to 1.00, almost perfect.17 A 2- 
sided P<0.05 was considered to be statistically signifi-
cant. All statistical analyses were performed with IBM 
SPSS Statistics, version 23.0 (IBM Corp, Armonk, NY), 
and graphs were created with GraphPad Prism, ver-
sion 8.4.2 (GraphPad Software, La Jolla, CA).
RESULTS
Patients’ Characteristics
The patients’ characteristics are summarized in Table 1. 
The patients’ mean age was 60.0±13.1  years, 54% 
were women, with a body mass index of 29.2±6.8 kg/
m2. Mean 24- hour ambulatory blood pressures were 
133.8/81.4±16.1/10.4  mm  Hg, despite the prescrip-
tion of 3.8±1.4 antihypertensive drugs. In total, 59% of 
the patients were completely (all drugs detectable in 
urine, 66% after correcting for single- pill combinations) 
and 29% partially adherent (1 drug not detectable 
urine, 23% after correcting for single- pill combina-
tions) to their prescribed antihypertensive medication. 
Adherence rates were highest when using urine as the 
matrix for LC- HRMS/MS (Figure 1). Adherent patients 
were prescribed to fewer antihypertensive drugs and 
daily doses (Figure 2) and had lower 24- hour ambu-
latory systolic and diastolic blood pressures com-
pared with nonadherent or partially adherent patients 
(Table  1). Except for mineralocorticoid receptor an-
tagonists (P=0.042), α- 1 blockers (P=0.008), and α- 2 
agonists (P=0.008), there was no difference in pre-
scribed drug classes between completely adherent, 
partially adherent, and nonadherent patients (Table 
S3). Figure 3 depicts the adherence rates for each an-
tihypertensive drug class.
Comparison of Detection Methods
Figure  4 shows an example of an LC- MS spectrum 
for the same sample in urine, plasma, and OF. In total, 
215 antihypertensive drugs were prescribed, of which 
182 drugs (parent and/or their metabolites) were de-
tected. Using LC- HRMS/MS analysis, most antihyper-
tensive medications were identified in urine, followed 
by plasma and OF (181 versus 119 versus 88; P<0.001; 
Figure 5). For all substance classes but alpha-1 block-
ers, detection rates of LC- HRMS/MS were highest 
in the urine. The overall detection rates of drugs with 
acidic functions, such as angiotensin- converting en-
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thiazides, were low in OF. However, there was no sta-
tistical difference in the frequency of detecting calcium 
channel blockers (P=0.727), β blockers (P=1.000), 
thiazides (P=0.125), and α- 2 agonists (P=0.125) be-
tween LC- HRMS/MS analyses of OF and plasma sam-
ples. Compared with urine, there was no significant 
difference in the detection of calcium channel blocker 
(P=0.063) and β blockers (P=1.000) in OF. Of note, de-
tection rates of drugs in OF were not different in pa-
tients with or without concomitant medication, known 
to possibly (eg, domperidone; P=0.651) or commonly 
(eg, amiodarone; P=0.702) cause hyposalivation. 
Table 1. Patients’ Characteristics
Characteristic
Nonadherent Patients Partially Adherent Patients Fully Adherent Patients
P ValueValue N Value N Value N
Age, y 64.0±8.7 6 56.2±13.4 13 59.1±13.7 37 0.400
Women, n (%) 5 (83) 6 8 (62) 13 17 (46) 37 0.249*
Body mass index, kg/m2 26.1±8.2 4 30.0±6.5 11 29.3±6.9 36 0.695
Current smoker, n (%) 2 (33) 6 4 (31) 13 9 (24) 37 0.726*
Type 2 diabetes mellitus, 
n (%)
1 (17) 6 3 (23) 13 10 (27) 37 0.908*
Coronary artery disease, n (%) 3 (50) 6 2 (15) 13 8 (22) 37 0.242*
Chronic heart failure, n (%) 3 (50) 6 3 (23) 13 14 (38) 37 0.434*
eGFR <60 mL/min per 
1.73 m2, n (%)
0 (0) 6 2 (17) 12 8 (23) 35 0.575*
Office systolic BP, mm Hg 155.5±37.3 6 143.9±24.7 12 142.3±24.7 36 0.666
Office diastolic BP, mm Hg 90.2±22.5 6 90.5±19.1 12 83.1±12.3 36 0.507
24- h Systolic BP, mm Hg 147.0±17.1 5 141.7±14.1 10 128.4±14.4 27 0.012
24- h Diastolic BP, mm Hg 81.6±9.3 5 90.0±9.3 10 77.7±9.2 27 0.009
Heart rate, bpm 80.5±15.6 6 79.6±18.3 12 78.0±11.8 35 0.950
Values are mean±SD or number (percentage). P values are given for between- group comparisons. BP indicates blood pressure; bpm, beats per minute; and 
eGFR, estimated glomerular filtration rate.
*Fisher’s exact test. Adherence rates were corrected for single- pill combinations.
Figure 1. Assessment of adherence rates using liquid chromatography coupled to high-resolution mass spectrometry (LC- 
HRMS/MS) in urine, plasma, and oral fluid.
A, Patients were considered “adherent” if ≥80% of the prescribed drugs were detectable in the matrices. B, Patients were classified 
as “adherent” if all prescribed drugs were detected. If 1 or at least 2 of the prescribed drugs were not detectable, the patient was 
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Furthermore, there were no differences in detection 
rates in patients with conditions known to impact sali-
vation, such as diabetes mellitus (P=0.626) or chronic 
kidney disease (estimated glomerular filtration rate 
<60 mL/min per 1.73 m2; P=0.059). Interrater agree-
ment was assessed for urine, plasma, and OF samples 
of 56 patients. For drug detection, Cohen’s κ ranged 
from 0.14 to 1.00 for urine and plasma samples, from 
−0.14 to 0.87 for urine and OF samples, and from 0.31 
to 1.00 for plasma and OF samples (Table 2).
DISCUSSION
Detection rates by LC- HRMS/MS for all substance 
classes but α- 1 blockers were highest in the urine. 
Antihypertensive drugs without acidic components 
had similar detection rates in plasma and OF, whereas 
antihypertensive drugs with acidic functions were 
poorly detected in OF.
In this study, 59% of the patients were completely 
(66% after correcting for single- pill combinations) 
Figure 2. Impact of dosing regimen on adherence.
The impact of the total number of antihypertensive drugs (A) and dosing frequency (B) on adherence to antihypertensive drugs. 
Adherence rates were corrected for single- pill combinations. P values are given for between- group comparisons.
Figure 3. Adherence rates for different substance classes. 
Adherence rates were corrected for single- pill combinations. *The overall number of drugs detected 
includes triamterene. As only one patient was prescribed to triamterene, potassium- sparing diuretics 
are not explicitly depicted in the figure. ACEi indicates angiotensin- converting enzyme inhibitor; ARB, 





 http://ahajournals.org by on O
ctober 5, 2020
J Am Heart Assoc. 2020;9:e014180. DOI: 10.1161/JAHA.119.014180 6
Lauder et al Antihypertensive Drug Detection in Oral Fluid
adherent to their prescribed antihypertensive medica-
tion, whereas 29% (23% after correcting for single- pill 
combinations) were partially adherent and 13% (11% 
after correcting for single- pill combinations) were non-
adherent. The relatively high rate of poor adherence 
to antihypertensive medication in this study is in line 
Figure 4. Example of liquid chromatography coupled to high-resolution mass spectrometry (LC- 
HRMS/MS) chromatograms.
The figure shows reconstructed LC- HRMS/MS chromatograms (BCD protonated molecule; AE1E2 
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with previous studies using LC- HRMS/MS urine anal-
ysis.18–20 In hypertension, evidence suggests that non-
adherence represents an important problem in routine 
care. Approximately one third of the hypertensive pa-
tients do not initiate a new prescription of antihyperten-
sive drugs,2 and almost half of the patients who were 
prescribed an antihypertensive medication become 
nonadherent within 1 year.16 Nonadherence to the an-
tihypertensive medication has also been shown to be 
associated with increased cardiovascular risk.1–4
The 2018 European Society of Cardiology/European 
Society of Hypertension guidelines for the management 
of arterial hypertension12 have put a strong emphasis 
on evaluating potential nonadherence as a major cause 
of insufficient blood pressure control and recommend 
drug monitoring to improve blood pressure control.12,21,22 
Although toxicological analyses using LC- HRMS/MS of 
urine and plasma are regarded as the most accurate 
method for the assessment of adherence, their use in 
clinical practice is often limited. There is an unmet need to 
develop an easily applicable, reliable method of drug de-
tection, which can be implemented in the management 
of patients with hypertension without requiring invasive 
sampling and sophisticated instrumentation on site.10–12 
In this context, we evaluated the feasibility of adherence 
monitoring of antihypertensive drugs in OF when com-
pared with urine and plasma. In contrast to venous 
plasma, sampling of OF is performed noninvasively and, 
therefore, neither requires medical personnel nor causes 
discomfort, which may negatively impact patient compli-
ance, especially in the setting of clinical studies. Unlike 
plasma sampling, OF collection can also easily be done in 
an “out- of- office” setting as the shipping and processing 
of OF samples does not require special capabilities.
Using LC- HRMS/MS analysis, most antihyperten-
sive drugs were detected in urine, followed by plasma 
and OF. Most drugs appear to enter the saliva by 
passive diffusion. The saliva/plasma ratio of drugs 
depends, among others, on the concentration gra-
dient of the free (unbound) fraction of the drug in the 
blood, the pH of OF and blood, the protein binding 
of the drug, and its acid dissociation constant.23,24 
For acidic and highly protein- binding drugs, the equi-
librium generally favors blood.25,26 Consequently, 
detection rates for angiotensin- converting enzyme 
inhibitors, angiotensin II receptor blockers, and thia-
zides were low in OF and high in plasma and urine. For 
calcium channel blockers, however, detection rates in 
OF were comparable to urine (P=0.063) and plasma 
(P=0.727). As single- pill combinations comprising 
Figure 5. Comparison of detection rates between matrices.
The figure depicts the detection rates of antihypertensive drugs in urine, plasma, and oral fluids. †The number of drugs detected 
was corrected for single- pill combinations. *The overall number of drugs detected includes triamterene. As only one patient was 
prescribed to triamterene, potassium- sparing diuretics are not explicitly depicted in the figure. P values were calculated for the 
comparison between all matrices (Cochran’s Q test) and between- group comparisons of oral fluid with plasma or urine (McNemar’s 
test). ACEi indicates angiotensin- converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, β blocker; CCB, calcium 
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a renin- angiotensin system inhibitor in conjunction 
with a calcium channel blocker or diuretic are recom-
mended as initial therapy in most patients, the de-
tection of one of these substances may be sufficient 
enough to screen for adherence. Drug adherence 
monitoring in urine alone may cause false- positive 
results because the washout period for several an-
tihypertensive drugs in urine lasts longer than multi-
ple half- lives, usually >24 hours.10 Less is known on 
the detection time of drugs in OF. However, for drugs 
of abuse, detection times are far shorter in OF than 
in urine.27 Urine may still be the matrix of choice for 
qualitative analyses, such as adherence screening in 
general, but an additional LC- HRMS/MS analysis of 
plasma or OF should be considered to assess recent 
drug intake. Although the present study analyzed the 
feasibility of qualitative analyses of antihypertensive 
drugs, recent data indicate that OF can be used for 
quantitative analyses similarly.28,29
The OF is secreted by 3 pairs of salivary glands 
(parotid, submandibular, and sublingual glands), 
the gingival cervicular sulci, and hundreds of minor 
accessory salivary glands.30 The sympathetic and 
parasympathetic nervous system regulates salivation 
and follows a circadian pattern.30 A higher saliva-
tory flow rate is associated with higher bicarbonate 
concentrations and pH.24,30,31 The pH of OF highly 
depends on physiological conditions and can range 
from 6.0 to 8.0.24,30,31 Under resting conditions, the 
pH of OFs is stabilized at ≈7.0.30 When collecting OF, 
several factors have to be considered, which may in-
fluence salivation. These include the patient’s diet, 
emotional states (eg, hunger and anxiety), medica-
tions (antidepressants), and medical conditions (cys-
tic fibrosis, diabetes mellitus, and end- stage renal 
disease).25,30,32,33 Therefore, sampling of OF should 
be performed under standardized conditions (at the 
same daytime and during rest). However, herein, 
there was no difference in detection rates for patients 
with or without diabetes mellitus (P=0.626), chronic 
kidney disease (P=0.059), or drugs known to influ-
ence salivation (P>0.651).
LIMITATIONS
This study was primarily designed to assess the fea-
sibility of adherence monitoring of antihypertensive 
drugs in OF as a noninvasively accessible matrix. In 
this feasibility study, the sample size was relatively 
low and was not based on a priori power calcula-
tion. The results should be regarded as hypothesis 
generating and need validation in larger cohorts. As 
with all cross- sectional studies, measuring drug ad-
herence at one occasion only incompletely reflects 
the dynamic process of a patient’s drug- taking be-
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prescribed drug, the implementation of the dosing 
regimen, and its discontinuation.34 The study pro-
tocol did not require directly observed drug intake. 
As most drugs enter saliva by passive diffusion, the 
saliva/plasma ratio does not only depend on the con-
centration gradient but also the pH of OF, which can 
be influenced by drugs, medical conditions, and the 
autonomic nervous system.
CONCLUSIONS
Although more drugs were detectable in urine, this 
study showed the feasibility of detecting several antihy-
pertensive drugs or their compounds in OF. Therefore, 
drug adherence testing in OF should further be inves-
tigated as a noninvasive approach, not requiring medi-
cal personnel, and can be directly observed without 
interfering with the patient’s privacy.
PERSPECTIVES
Assessing drug adherence in hypertensive patients 
might reduce the number of unnecessarily prescribed 
drugs. In patients with apparently treatment- resistant 
hypertension, therapeutic drug monitoring was shown 
to improve blood pressure control. LC- HRMS/MS of 
urine and plasma is regarded as the most accurate 
method for the assessment of adherence. However, 
there is an unmet need for an easily applicable, cost- 
effective, and reliable method to evaluate drug adher-
ence, with no need for invasive sampling at best. Drug 
adherence testing in OF is feasible for several antihy-
pertensive drugs and should further be investigated 
as a noninvasive approach, which can also easily be 
done in an “out- of- office” setting.
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Table S1. Patients’ characteristics. 
 Non adherent Adherent p-value 
Value N Value N 
Age, years 59.9±8.8 13 58.7±14.3 43 0.930 
Female, n (%) 8 (62) 13 22 (51) 43 0.545 
Body mass index, kg/m2 26.2±5.9 10 30.0±6.8 41 0.145 
Current smoker, n (%) 5 (38) 13 10 (23) 43 0.302 
Diabetes mellitus type II, n (%) 2 (15) 13 12 (29) 41 0.475 
Coronary heart disease, n (%) 5 (38) 13 8 (20) 41 0.262 
Chronic heart failure, n (%) 5 (38) 13 15 (37) 41 1.000 
eGFR <60 mL/min/1.73 m2, n (%) 1 (8) 12 9 (23) 40 0.420 
Office systolic BP, mmHg 150.1±31.4 12 142.4±24.4 42 0.466 
Office diastolic BP, mmHg 89.8±18.5 12 84.3±14.3 42 0.338 
24-hour systolic BP, mmHg 146.1±14.4 9 130.4±15.0 33 0.010 
24-hour diastolic BP, mmHg 86.3±9.1 9 79.7±10.4 33 0.075 
Heart rate, bpm 82.1±17.2 12 77.7±12.5 41 0.807 
 
 
Values are mean ± standard deviations (SD) or numbers (%). *p-values for between group 
comparisons. Adherence rates were corrected for single-pill combinations. BP, blood 
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Table S2. Prescribed antihypertensive medication for non-adherent and adherent 
patients. 
 Non adherent Adherent p-value 
Value N Value N 
Antihypertensive drugs prescribed, n 4.4±1.3 13 3.7±1.3 43 0.128 
Daily doses of antihypertensive drugs, n 5.6±1.9 13 4.7±2.3 43 0.114 
Single-pill combinations, n (%) 5 (38) 13 15 (35) 43 1.000 
Angiotensin-converting enzyme inhibitor, n 
(%) 
6 (46) 13 12 (28) 43 0.310 
Angiotensin II receptor blocker, n (%) 8 (62) 13 28 (65) 43 1.000 
Calcium channel blocker, n (%) 9 (69) 13 24 (56) 43 0.525  
Thiazide, n (%) 7 (54) 13 23 (53) 43 1.000 
Loop diuretic, n (%) 3 (23) 13 14 (33) 43 0.733 
Triamterene, n (%) 0 (0) 13 1 (2) 43 1.000 
Beta blocker, n (%) 12 (92) 13 36 (84) 43 0.665 
Mineralocorticoid receptor antagonist, n (%) 5 (38) 13 10 (23) 43 0.302 
Alpha-1 blocker, n (%) 2 (15) 13 1 (2) 43 0.131 
Alpha- 2 agonist, n (%) 6 (46) 13 8 (19) 43 0.067 
 
Values are mean ± standard deviations (SD) or numbers (%). p-values for between group 
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Value N Value N Value N 
Antihypertensive drugs 
prescribed, n 
5.3±1.2 6 4.5±1.1 13 3.4±1.2 37 <0.001 
Daily doses of antihypertensive 
drugs, n 
6.3±2.3 6 6.1±2.4 13 4.2±1.9 37 0.012 
Single-pill combinations, n (%) 3 (50) 6 4 (31) 13 13 (35) 37 0.829† 
Angiotensin-converting enzyme 
inhibitor, n (%) 
2 (33) 6 5 (39) 13 11 (30) 37 0.906† 
Angiotensin II receptor blocker, 
n (%) 
5 (83) 6 8 (62) 13 23 (62) 37 0.788† 
Calcium channel blocker, n (%) 5 (83) 6 8 (62) 13 20 (54) 37 0.500† 
Thiazide, n (%) 5 (83) 6 7 (54) 13 18 (49) 37 0.329† 
Loop diuretic, n (%) 1 (17) 6 5 (39) 13 11 (30) 37 0.676† 
Triamterene, n (%) 0 (0) 6 1 (8) 13 0 (0) 37 0.339† 
Beta blocker, n (%) 6 (100) 6 12 (92) 13 30 (81) 37 0.601† 
Mineralocorticoid-receptor 
antagonist, n (%) 
3 (50) 6 6 (46) 13 6 (16) 37 0.042† 
Alpha-1 blocker, n (%) 2 (33) 6 1 (8) 13 0 (0) 37 0.008† 
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Values are mean ± standard deviations (SD) or numbers (%). p-values for between group 
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